Stocktoria
GERON CORP GERN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1996-07-31
GERON CORP statistics & valuation
Market cap$846.8M
P / B3.7×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | — | -81832.9% | -23246.6% | -8183.7% |
| Net margin | — | — | -77690.7% | -23808.9% | -8335.4% |
| FCF margin | — | — | -71127.8% | -21444.6% | -6874.6% |
| Return on assets | -14.6% | -29.4% | -46.7% | -74.5% | -51.4% |
| Return on equity | -37.0% | -62.3% | -74.3% | -177.4% | -91.8% |
| Debt / equity | 0.53× | 0.42× | 0.14× | 0.38× | 0.39× |
| Current ratio | 4.66 | 5.56 | 3.16 | 2.35 | 4.11 |
| Revenue growth | — | — | -60.2% | -57.2% | 450.6% |
Source: SEC EDGAR filings · CIK 0000886744 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.